Overexpression of EIF5A2 Predicts Poor Prognosis in Patients with Oral Squamous Cell Carcinoma.
EIF5A2
epithelial–mesenchymal transition
eukaryotic translation initiation factor 5A2
oral cancer
oral squamous cell carcinoma
overall survival
prognosis
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
27 Jun 2020
27 Jun 2020
Historique:
received:
15
05
2020
revised:
17
06
2020
accepted:
25
06
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
Oral squamous cell carcinoma (OSCC) is the most common epithelial malignancy affecting the oral cavity, and it is especially significant in Asian countries. Patients diagnosed with OSCC have an unfavorable prognosis and additional prognostic markers would help improve therapeutic strategies. We sought to investigate the association between eukaryotic translation initiation factor 5A2 (EIF5A2) and epithelial-mesenchymal transition (EMT) markers as well as the prognostic significance of EIF5A2 in OSCC. The expression of EIF5A2 and EMT markers was measured through the immunohistochemical staining of specimens from 272 patients with OSCC. In addition, the correlation between different clinicopathological factors and EIF5A2 expression was analyzed. The prognostic role of EIF5A2 was then analyzed via Kaplan-Meier analysis and Cox proportional hazard models. Among the 272 patients, high EIF5A2 expression was significantly associated with an advanced N value (
Identifiants
pubmed: 32605067
pii: diagnostics10070436
doi: 10.3390/diagnostics10070436
pmc: PMC7400414
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Chung Shan Medical University Hospital
ID : CSH-2018-C-001
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Am J Transl Res. 2018 Dec 15;10(12):4269-4279
pubmed: 30662669
Br J Cancer. 2014 Jan 21;110(2):399-408
pubmed: 24178756
Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jun;115(6):789-98
pubmed: 23706919
Carcinogenesis. 2017 Jan;38(1):94-104
pubmed: 27879277
PLoS One. 2015 Mar 20;10(3):e0119229
pubmed: 25793713
Br J Cancer. 2014 Apr 2;110(7):1767-77
pubmed: 24504366
Biochim Biophys Acta. 2015 Jul;1849(7):836-44
pubmed: 25979826
Transl Oncol. 2017 Jun;10(3):396-409
pubmed: 28433800
Front Pharmacol. 2012 Jul 30;3:149
pubmed: 23060791
J Cancer Res Ther. 2016 Apr-Jun;12(2):486-92
pubmed: 27461598
Clin Cancer Res. 2011 Sep 15;17(18):5991-9
pubmed: 21807637
Breast Cancer. 2015 Nov;22(6):602-7
pubmed: 24638963
Eur J Biochem. 2003 Nov;270(21):4254-63
pubmed: 14622290
Gut. 2012 Apr;61(4):562-75
pubmed: 21813470
BMC Cancer. 2016 Aug 22;16:669
pubmed: 27549330
Hum Pathol. 2008 Jan;39(1):80-6
pubmed: 17949776
Exp Ther Med. 2019 May;17(5):3741-3747
pubmed: 30988760
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Biochem Biophys Res Commun. 2009 Jun 12;383(4):497-502
pubmed: 19379712
BMC Cancer. 2014 Dec 15;14:951
pubmed: 25511643
Ann Surg Oncol. 2007 Mar;14(3):1058-64
pubmed: 17106627
Br J Cancer. 2017 Sep 5;117(6):856-866
pubmed: 28751758
Cancer Cell Int. 2015 Nov 17;15:109
pubmed: 26581310
Hepatology. 2010 Apr;51(4):1255-63
pubmed: 20112425
J Pathol. 2003 Oct;201(2):268-77
pubmed: 14517844
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
pubmed: 15761078
ISRN Oncol. 2012;2012:681469
pubmed: 22548191
Adv Dent Res. 2011 May;23(2):237-46
pubmed: 21490236
Clin Cancer Res. 2013 Aug 1;19(15):4092-103
pubmed: 23743567
Int J Mol Sci. 2016 Jun 24;17(7):
pubmed: 27347940
Gynecol Oncol. 2009 Feb;112(2):314-8
pubmed: 19054548
Oncol Rep. 2018 Mar;39(3):1283-1291
pubmed: 29286162
Genomics. 2001 Jan 1;71(1):101-9
pubmed: 11161802
Otolaryngol Head Neck Surg. 2005 Jun;132(6):862-8
pubmed: 15944556
Oncol Lett. 2018 Apr;15(4):4541-4549
pubmed: 29541224
PLoS One. 2012;7(11):e50104
pubmed: 23185547
Sci Signal. 2014 Sep 23;7(344):re8
pubmed: 25249658